135 related articles for article (PubMed ID: 12369610)
21. The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression.
Redmond AM; Kelly JP; Leonard BE
Pharmacol Biochem Behav; 1999 Apr; 62(4):619-23. PubMed ID: 10208367
[TBL] [Abstract][Full Text] [Related]
22. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
Sugawara Y; Higuchi H; Yoshida K; Takahashi H; Kamata M; Naito S; Sato K; Shimizu T
Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
[TBL] [Abstract][Full Text] [Related]
23. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Fawcett J; Barkin RL
J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
[TBL] [Abstract][Full Text] [Related]
24. Levomilnacipran (Fetzima) a new SNRI for depression.
Med Lett Drugs Ther; 2013 Dec; 55(1432):101-2. PubMed ID: 24419243
[No Abstract] [Full Text] [Related]
25. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.
Ansseau M; von Frenckell R; Mertens C; de Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P; Dejaiffe G
Psychopharmacology (Berl); 1989; 98(2):163-8. PubMed ID: 2569214
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
28. Milnacipran: new preparation. Tricyclics remain first-line antidepressants.
Prescrire Int; 1998 Apr; 7(34):51-3. PubMed ID: 10183385
[TBL] [Abstract][Full Text] [Related]
29. [Clinical tolerance of a new antidepressant -- milnacipran].
Regina W; Vandel P; Vandel S; Sechter D; Bizouard P
Encephale; 1999; 25(3):252-8. PubMed ID: 10434151
[TBL] [Abstract][Full Text] [Related]
30. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and safety: essentials in antidepressant pharmacotherapy.
Lader MH
J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of milnacipran in comparison with other antidepressants.
Puozzo C; Leonard BE
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():15-27. PubMed ID: 8923123
[TBL] [Abstract][Full Text] [Related]
33. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders.
Macher JP; Sichel JP; Serre C; Von Frenckell R; Huck JC; Demarez JP
Neuropsychobiology; 1989; 22(2):77-82. PubMed ID: 2701744
[TBL] [Abstract][Full Text] [Related]
34. Hypertension induced by regular doses of milnacipran: a case report.
de Toledo Ferraz Alves TC; Guerra de Andrade A
Pharmacopsychiatry; 2007 Jan; 40(1):41-2. PubMed ID: 17327962
[No Abstract] [Full Text] [Related]
35. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
36. Milnacipran: a unique antidepressant?
Kasper S; Pail G
Neuropsychiatr Dis Treat; 2010 Sep; 6(Suppl I):23-31. PubMed ID: 20856597
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
38. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group.
Rouillon F; Warner B; Pezous N; Bisserbe JC
Int Clin Psychopharmacol; 2000 May; 15(3):133-40. PubMed ID: 10870871
[TBL] [Abstract][Full Text] [Related]
39. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor.
Boyer P; Briley M
Drugs Today (Barc); 1998 Aug; 34(8):709-20. PubMed ID: 14988777
[TBL] [Abstract][Full Text] [Related]
40. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life.
Rouillon F; Berdeaux G; Bisserbe JC; Warner B; Mesbah M; Smadja C; Chwalow J
J Affect Disord; 2000 Jun; 58(3):171-80. PubMed ID: 10802126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
